SecBot SecBot
COURT-RULING ·Filed May 27, 2026

AZN

ASTRAZENECA PLC
NEUTRAL
Impact 4/10
Horizondays Processed5mo ago CourtCourt Ruling · courtlistener.com
Court ruling (appellate)
Actionable Insight • Neutral

The $11.1M award is immaterial for a $580B market cap company. The denial of the ~$375M speculative damages claim removes a potential overhang. This ruling closes a legacy acquisition dispute with no ongoing operational impact. No trading action warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$185.62
T+0 close · May 27, 2026 · via day close
Latest settled
−11.39%
T+60 · $164.48
Vs SPY
−13.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $185.62entry
  2. T+1 · 6mo ago −0.15%α −0.70% · $185.34
  3. T+5 · 6mo ago −4.40%α −5.61% · $177.45
  4. T+20 · 5mo ago −1.40%α +0.90% · $183.02
  5. T+60 · 3mo ago −11.39%α −13.01% · $164.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The Delaware Court of Chancery ruled that Syntimmune (acquired by AstraZeneca/Alexion) breached its merger agreement representation regarding cGMP compliance of drug substance and drug product lots. The court awarded AstraZeneca approximately $11.1 million in indemnification for replacement manufacturing costs, but denied its claim for ~$375 million in benefit-of-the-bargain damages as speculative. The ruling is a modest financial win for AZN but represents a small fraction of the $580B market cap.

Court Ruling Details

Ruling Date
May 27, 2026
Court
Court of Chancery of the State of Delaware
Court Level
Appellate
Judge
Morgan T. Zurn
Case Type
contract
Ruling Type
final judgment
Outcome
PARTIAL: mixed ruling, some claims won/lost
Damages Awarded
$11.1M
Precedent Risk
LOW

Key Facts

  • Court found Syntimmune breached Section 4.13(a) of the merger agreement by failing to manufacture drug lots in compliance with cGMP standards
  • AstraZeneca awarded $11,115,556.33 in indemnification for replacement drug substance and drug product costs
  • Court denied AstraZeneca's claim for ~$375 million in benefit-of-the-bargain damages as entirely speculative and unsupported by evidence
  • The ruling resolves a post-acquisition dispute over contaminated drug materials that caused clinical trial delays
  • Drug substance lots had excessive host cell protein and DNA contamination due to manufacturing process changes at AGC Biologics
  • Drug product lots were contaminated with particulates after Patheon switched manufacturing suites without proper evaluation

Financial Impact

$11.1 million indemnification award to AstraZeneca, representing ~0.002% of market cap

indemnification

Risk Factors

  • No material financial risk identified, award is de minimis relative to market cap
  • No ongoing operational impact, clinical trials were already restarted

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-3p4edalk-AZN

Track record

77 reports on AZN

Performance horizon

19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published May 27, 2026